Analysts: CBS May Buy Back Shares and 4 More Research Notes to Review Now
March 14, 2013
Acadia Pharmaceuticals (NASDAQ:ACAD): Roth Capital is convinced that a Phase III trial of ACADIA’s pimavanserin for psychosis in Parkinson’s disease showed strong efficacy results supporting the $1 billion potential for the drug. The firm keeps its Buy rating and an $11 price target on the stock.
Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!
Premium Newsletters
Gold & Silver
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More
Commodities Premium
There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more
ETF Investing
At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more
Wall St. Cheat Sheet has been featured in these fine media outlets:
